High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)
Recruiting
This is a randomized study of the European SIOP Neuroblastoma Group (SIOPEN) in high-risk neuroblastoma (stages 2, 3, 4 and 4s MYCN-amplified neuroblastoma, stage 4 MYCN non amplified \> 12 months at diagnosis). The protocol consists of a rapid, dose intensive induction chemotherapy, peripheral blood stem cell harvest, attempted complete excision of the primary tumour, myeloablative therapy followed by peripheral blood stem cell rescue, radiotherapy to the site of the primary tumour and immunot... Read More
Gender:
ALL
Ages:
Between 1 month and 21 years
Trial Updated:
10/21/2020
Locations: Women and Children´s Hospital, Adelaide, Not set +125 locations
Conditions: Neuroblastoma
BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab
Terminated
The trial will determine the value of adding bevacizumab to chemotherapy plus trastuzumab in patients with resected node-positive or high risk node-negative, HER2-positive breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
09/09/2020
Locations: University of Alabama at Birmingham, Birmingham, Alabama +648 locations
Conditions: Breast Cancer
Combination Chemotherapy in Treating Young Patients With Hodgkin's Lymphoma
Completed
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating Hodgkin's lymphoma. PURPOSE: This randomized phase III trial is studying different combination chemotherapy regimens to compare how well they work in treating young pati... Read More
Gender:
ALL
Ages:
17 years and below
Trial Updated:
03/24/2020
Locations: Universitaetsklinikum Giessen-Marburg, Giessen, Not set +1 locations
Conditions: Lymphoma
Vaccination in Prostate Cancer (VANCE)
Completed
This is a clinical trial of a new treatment for prostate cancer that is a type of vaccine that could be a new way to treat cancer. A vaccine that could alert the immune system to the presence of cancer cells in the body may enable the immune system to target and kill those cells effectively. This vaccine is intended to work by making the immune system kill cells that have a special protein (called 5T4) that is present on the surface of cancer cells. The vaccine is made up of two recombinant viru... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
02/07/2020
Locations: University of Oxford, Oxford, Not set +1 locations
Conditions: Prostate Cancer
IMA970A Plus CV8102 in Very Early, Early and Intermediate Stage Hepatocellular Carcinoma Patients
Completed
This study is being carried out in order to evaluate a new cancer vaccine called IMA970A combined with CV8102, a new adjuvant for the treatment of liver cancer (hepatocellular carcinoma). It will be investigated whether IMA970A and CV8102 is safe and can trigger an immune response against the tumor, which may prevent the tumor (cancer) from recurring or spreading or may even lead to tumor shrinkage following the standard treatments the patients have previously received.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/31/2020
Locations: Universitair Ziekenhuis Antwerpen (UZA), Division of Gastroenterology and Hepatology, Edegem, Not set +5 locations
Conditions: Hepatocellular Carcinoma
BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)
Completed
BBR 2778 is a novel aza-anthracenedione that has activity in experimental tumors and shows reduced potential for cardiotoxicity in animal models. This cytotoxic agent has structural similarities with mitoxantrone as well as general similarities with anthracyclines (such as the tricyclic central quinoid chromophore).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/27/2020
Locations: Robert A. Moss, M.D., FACP, Inc., Fountain Valley, California +98 locations
Conditions: Lymphoma, Non-Hodgkin
Phase II Randomised Trial of Cyclophosphamide and Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma.
Unknown
This study evaluates a new treatment combination of ixazomib with cyclophosphamide and dexamethasone in relapsed or refractory multiple myeloma. Participants will either receive ixazomib with cyclophosphamide and dexamethasone or cyclophosphamide and dexamethasone alone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/21/2020
Locations: Queen Elizabeth Medical Centre, Birmingham, Not set +17 locations
Conditions: Multiple Myeloma
Safety & Efficacy Study of EGF Cancer Vaccine to Treat Stage IV Biomarker Positive, Wild Type EGF-R NSCLC Patients
Terminated
The vaccine contains humanized recombinant antigen (EGF - Epithelial Growth Factor) and an adjuvant. The antibodies induced by vaccination will react with circulating EGF leading to removal of EGF from the circulation. As a result, binding to its target EGF-Receptor is prevented. Blocking of EGF-Receptor is preventing activation and stimulation of proliferation of tumour cell. A Phase 3 clinical trial on the EGF vaccine is ongoing in Cuba. The result from previous studies demonstrated positive c... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/09/2019
Locations: "Multiprofile Hospital for Active Treatment (MHAT)-Dobrich" AD, Dobrich, Not set +50 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia
Unknown
RATIONALE: Giving chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving cyclosporine, me... Read More
Gender:
ALL
Ages:
1 year and below
Trial Updated:
07/29/2019
Locations: Children's Hospital Boston, Boston, Massachusetts +12 locations
Conditions: Leukemia
Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma
Completed
This is a phase 1 trial designed to evaluate safety and tolerability of chemotherapy in combination with inotuzumab ozogamicin, an investigational product, in adults with CD22-positive non-Hodgkin's lymphoma. The trial will involve two arms. In one arm, subjects will receive chemotherapy regimen R-CVP (rituximab, cyclophosphamide, vincristine and prednisone). In the other arm, subjects will receive R-GDP (rituximab, gemcitabine, cisplatinum and dexamethasone). Subjects in both arms will also rec... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2019
Locations: Davis Cancer Pavillion and Shands Medical Plaza, Gainesville, Florida +27 locations
Conditions: Lymphoma, B-Cell
A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)
Terminated
This open-label, randomized, parallel group study will evaluate the efficacy and safety of obinutuzumab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisolone or prednisone (CHOP) chemotherapy versus rituximab (MabThera/Rituxan) with CHOP in previously untreated participants with cluster of differentiation 20 (CD20)-positive diffuse large B-cell lymphoma (DLBCL). Participants will be randomized to receive either obinutuzumab 1000 milligrams (mg) intravenously (IV) every... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/08/2019
Locations: University of Alabama at Birmingham, Birmingham, Alabama +234 locations
Conditions: Diffuse Large B-Cell Lymphoma
Phase III, Multicentre, Randomised Study of Fludarabine/Cyclophosphamide Combination With or Without Rituximab in Patients With Untreated Mantle Cell Lymphoma
Completed
This randomized phase III trial is comparing how well fludarabine and cyclophosphamide work when given together with or without rituximab in treating patients with previously untreated mantle cell lymphoma.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
10/29/2018
Locations: Peter MacCallum Cancer Centre, East Melbourne, Victoria +66 locations
Conditions: Lymphoma